Fewer than one in 10 patients eligible to benefit from obesity jabs like Wegovy can access them, warns the World Health Organization as it issues its initial recommendations on the medications.
Considering over a billion individuals worldwide now obese, it is advocating for more widespread and fairer availability to this class of drugs.
According to forecasts, in excess of 2,000,000,000 will be obese by 2030 unless action is taken.
"Our new guidelines affirms that excess weight is a chronic disease that can be treated with holistic and lifelong support," stated the agency's head Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and supply-chain constraints are key obstacles to broad access to the treatments that can aid individuals in losing significant body mass, says the body.
Skinny Jab Supply Crisis
Even in the current most optimistic outlook, the manufacturing of these medications could only cover approximately 100 million people – fewer than 10% of those who need them, as stated by the WHO.
The advice encourages governments and firms to expand availability, through strategies including voluntary licensing.
The intellectual property rights on semaglutide – the main component of a leading brand – is due to expire in several nations in 2026.
How Obesity Drugs Work
The injections replicate a natural hormone to delay gastric emptying, curb appetite and enhance the sense of being full so people eat less.
Individuals usually start to lose weight within a few weeks of starting on the once-weekly jabs.
Studies indicates users may regain a significant portion within a year of discontinuing the drug, because their typical hunger come back.
Being above a healthy weight elevates your likelihood for experiencing health problems, like diabetes, cardiovascular issues, brain attack, and specific malignancies.
Excess weight affects people in every country and was associated with 3.7 million deaths worldwide in 2024, per the health agency.
